MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopamine"

  • 2022 International Congress

    Dynamic functional connectivity changes and striatal dopamine deficiency in Parkinson’s disease

    A. Asendorf, H. Theis, M. Tittgemeyer, L. Timmermann, G. Fink, A. Drzezga, M. Hoenig, T. van Eimeren (Cologne, Germany)

    Objective: Using a multimodal neuroimaging approach, we assessed whether striatal dopamine synthesis capacity modulates the temporal dynamics of FC in PD. Background: The novel approach…
  • 2022 International Congress

    Dopaminergic modulation of express reaching responses in Parkinson’s disease

    M. Gilchrist, R. Kozak, B. Corneil, P. Macdonald (London, Canada)

    Objective: This study investigates the role of dopamine (DA) in modulation of automatic stimulus-driven responses. We investigated the effect of PD, DA medication, and instruction…
  • MDS Virtual Congress 2021

    Do Parkinson’s disease medications have an effect on gut microbiome? A case-control study

    P. Zhang, P. Huang, Y. Qian, X. Yang, Y. He, J. Du, G. Li, S. Cui, S. Xu, J. Liu, Y. Lin, Y. Fu, G. He, Z. Zhang, Q. Xiao, S. Chen (Shanghai, China)

    Objective: To investigate the difference in the gut microbiota between drug-naïve and medicated PD patients and focus on the association between gut microbiota and anti-PD medications. Background:…
  • MDS Virtual Congress 2021

    Parkinson’s disease patients with hallucinations exhibit dopaminergic degeneration and cortical thinning

    C. Wertz, K. Poston, N. Shaff, A. Hartman, A. Horner, A. Mayer, A. Vakhtin, A. Deligtisch, S. Pirio Richardson, S. Ryman (Albuquerque, USA)

    Objective: Examine whether Parkinson’s disease patients (PD) who experience hallucinations (PD+hall) exhibit a greater decline in striatal dopamine and corresponding posterior cortical decline relative to…
  • MDS Virtual Congress 2021

    Multimodal, longitudinal investigation in Dopa-responsive dystonia

    A. Steinmeier, MG. Pauly, DM. Al-Shorafat, G. Saranza, AE. Lang, N. Brüggemann, V. Tadic, C. Klein, K. Lohmann, MJN. Brown, C. Beste, A. Münchau, T. Bäumer, A. Weissbach (Lübeck, Germany)

    Objective: To perform a detailed longitudinal clinical and neurophysiological investigation in monogenic Dopa-responsive dystonia (DRD) patients with mutations in the guanosine triphosphate cyclohydrolase 1 (GCH1)…
  • MDS Virtual Congress 2021

    Is Generalized and Segmental Dystonia Accompanied by Impairments of the Dopaminergic System?

    J. Ikezawa, F. Yokochi, R. Okiyama, S. Kumada, M. Tojima, T. Kamiyama, T. Hanakawa, H. Matsuda, F. Tanaka, Y. Nakata, E. Isozaki (Fuchu, Japan)

    Objective: To investigate functional dopaminergic impairments in dystonia, we compared patients with dystonia and Parkinson’s disease (PD) with normal controls using neuromelanin-sensitive magnetic resonance imaging…
  • MDS Virtual Congress 2021

    Connectomic Analysis of SNc and VTA Projections to the Striatum and Cortex

    N. Handfield-Jones, A. Owen, A. Khan, P. Macdonald (London, Canada)

    Objective: To investigate the dopaminergic neural tracts of healthy individuals using Diffusion MRI on Human Connectome Project Data. Background: Classically, the DA system has been…
  • MDS Virtual Congress 2021

    The effects of acute administration of VMAT2 inhibitors on extracellular levels of dopamine, norepinephrine, 5-HT and histamine in the striatum and medial prefrontal cortex

    E. Adler, L. Magid, O. Even-Chen, S. Schmidt, I. Cope, J. Alexander, J. Kehr, A. Orbach (Netanya, Israel)

    Objective: To evaluate the effects of reversible VMAT2 inhibitors (deutetrabenazine, tetrabenazine and valbenazine) on extracellular levels of monoamines and their acidic metabolites in rat striatum…
  • MDS Virtual Congress 2021

    Istradefylline/L-DOPA combination therapy for Parkinson’s disease and blood markers of glycolytic energy homeostasis

    NAO. Kanzato, KO. Nakachi, MA. Hayashi, F. Kinjyo, W. Mizuta, SA. Mochizuki (Haebaru-Cho, Okinawa, Japan)

    Objective: To clarify the potential to preserve glycolytic energy homeostasis (GEH) with the Istradefylline combined to L-DOPA (IST-LD), and to prevent LD-induced weight loss and…
  • MDS Virtual Congress 2021

    OPTIMIPARK Questionnaire:a tool to optimize treatment in Parkinson´s disease.

    J. Máñez-Miró, F. Vivancos-Matellano, L. Vela-Desojo, R. Martinez-Fernandez, F. Alonso-Frech, N. Lopez-Aristegui, E. Balaguer-Martínez, J. Martinez-Castrillo, L. Lopez-Manzanares, P. Martínez-Martín (Madrid, Spain)

    Objective: To validate the OPTIMIPARK questionnaire as a tool to help the clinician in the adjustment of dopaminergic treatment in Parkinson´s disease(PD). Background: At early…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 27
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley